Malignant Lymphoma Market Research Report- Global Forecast To 2022

Malignant Lymphoma Market Research Report- Global Forecast To 2022

ID: MRFR/HC/1329-HCRR | July, 2017 | Region: Global | 85 pages | Half-Cooked Research Reports

Malignant Lymphoma Market Information, by types (Hodgkin lymphoma and Non Hodgkin lymphoma), by treatment (chemotherapy, radiation therapy, immunotherapy, stem cell therapy and others) - Forecast to 2022


Study objectives of Malignant Lymphoma Market:



  • To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the malignant lymphoma market.

  • To provide insights about factors affecting the market growth

  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future prospective

  • To provide country level analysis of the market for segments by type, by treatment and its sub-segments.

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global malignant lymphoma market.



Malignant Lymphoma market, by Treatment:



Intended Audience



  • Malignant lymphoma drug manufacturers & Suppliers

  • Contract Research Organizations (CROs)

  • Research and Development (R&D) Companies

  • Government Research Laboratories

  • Independent Research Laboratories

  • Government and Independent Regulatory Authorities

  • Market Research and Consulting Service Providers

  • Academic Institutes and Universities


 Market Synopsis of Malignant Lymphoma Market:


Market Scenario:
The lymphatic system runs throughout our bodies. Cancers that develop anywhere in body’s lymphatic system are called as lymphoma and if they have the ability to spread in the body, they are called malignant lymphoma. The most common symptom of the lymphoma is swollen glands. Men are more prone to lymphoma compared to women for the reason unknown. Globally the market for malignant lymphoma is increasing rapidly. Globally the market for malignant lymphoma is expected to grow at the rate of about XX% from 2016 to 2022.


Key Finding



  • The malignant lymphoma global market and is expected to reach $XX billion by 2022.

  • Chemotherapy holds the largest share of XX% of the market.

  • North America holds the largest market share of XX% of malignant lymphoma market and is anticipated to reach $XX billion by the end of forecast period.

  • Globally, Asia-Pacific the fastest growing region and expected to grow at the rate of XX% during the forecast period.

  • Chemotherapy holds the largest market share in 2015, and expected to continue the similar growth throughout the forecast period.


Segments:                                                                                                                                       
Malignant lymphoma market has been segmented on the basis of types which comprises of Hodgkin lymphoma and non-Hodgkin lymphoma. On the basis of treatments, market is segmented into chemotherapy, radiation therapy, immunotherapy, stem cell therapy and others.


Regional Analysis of Malignant Lymphoma Market:                                            
Globally North America is the largest market for malignant lymphoma. Europe is the second-largest market. Furthermore Asia pacific market is expected to be the fastest growing market for malignant lymphoma.


Key Players for Malignant Lymphoma Market:                                           
Some of the key players in this market are: Abbott Laboratories, ABIOGEN PHARMA S.p.A., Actelion Pharmaceuticals, Aeterna Zentaris, Inc., Allos Therapeutics, Astellas Pharma, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Genmab, Inovio Pharmaceuticals, Johnson & Johnson, and Merck & Co. Inc., Novartis, Onyx Pharmaceuticals, Roche, Seattle Genetics and others    

North America



  • US

  • Canada

  • Europe


Western Europe



  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe


Asia



  • China

  • India

  • Japan

  • South Korea

  • Rest of AsiaPacific


Middle East & Africa

The report for Malignant Lymphoma Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions

TABLE OF CONTENTS

1          INTRODUCTION           

1.1        DEFINITION     

1.2        SCOPE OF STUDY      

1.2.1     RESEARCH OBJECTIVE          

1.2.2     ASSUMPTIONS & LIMITATIONS

1.2.2.1  ASSUMPTIONS

1.2.2.2  LIMITATIONS    

1.3        MARKET STRUCTURE:

2          RESEARCH METHODOLOGY   

2.1        RESEARCH PROCESS:           

2.2        PRIMARY RESEARCH 

2.3        SECONDARY RESEARCH:      

3          MARKET DYNAMICS   

3.1        DRIVERS         

3.2        RESTRAINTS               

3.3        OPPORTUNITIES         

3.4        MACROECONOMIC INDICATORS         

4          MARKET FACTOR ANALYSIS   

4.1        PORTERS FIVE FORCES MODEL        

4.2        BARGAINING POWER OF SUPPLIERS 

4.3        BARGAINING POWER OF BUYERS      

4.4        THREAT OF NEW ENTRANTS   

4.5        THREAT OF SUBSTITUTES      

4.6        INTENSITY OF RIVALRY           

5       GLOBAL MALIGNANT LYMPHOMA MARKET, BY TYPE

5.1       HODGKIN LYMPHOMA

5.2       NON-HODGKIN LYMPHOMA


  1.      GLOBAL MALIGNANT LYMPHOMA MARKET, BY OCCURANCE

6.1       LYMPH NODES

6.2       BONE MARROW

6.3       SPLEEN

6.4       BLOOD

6.5       OTHER ORGANS

7.         GLOBAL MALIGNANT LYMPHOMA MARKET, BY DIAGNOSTIC TESTS

7.1       IMMUNOPHENOTYPING

7.2       FLUORESCENCE IN SITU HYBRIDIZATION TESTING

7.3       FLOW CYTOMETER

8.         GLOBAL MALIGNANT LYMPHOMA MARKET

8.1       CHEMOTHERAPY

8.2       RADIATION THERAPY

8.3       IMMUNOTHERAPY

8.4       STEM CELL THERAPY

8.5       OTHERS

9.         GLOBAL MALIGNANT LYMPHOMA MARKET, BY REGION

9.1        INTRODUCTION

9.2        NORTH AMERICA

9.2.1     US

9.2.2     CANADA

9.3        EUROPE

9.3.1     WESTERN EUROPE

9.3.1.1  GERMANY

9.3.1.2  FRANCE

9.3.1.3  ITALY

9.3.1.3  SPAIN

9.3.1.5  UK

9.3.1.6  REST OF WESTERN EUROPE

9.3.2     EASTERN EUROPE

9.4        ASIA

9.4.1     JAPAN

9.4.2     CHINA

9.4.3     INDIA

9.4.4     AUSTRALIA

9.4.5     REPUBLIC OF KOREA

9.4.6     REST OF ASIA-PACIFIC

9.5        MIDDLE EAST & AFRICA

9.5.1     UNITED ARAB EMIRATES

9.5.2     SAUDI ARABIA

9.5.3     OMAN

9.5.4     KUWAIT

9.5.5     QATAR

9.5.6     REST OF MIDDLE EAST & AFRICA

10.        COMPETITIVE LANDSCAPE     

10.1      MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS         

10.1.1   STRATEGIC PARTNERSHIP     

10.1.2   MERGER & ACQUISITION        

11         COMPANY PROFILE    

11.1      ABBOTT LABORATORIES

11.1.1   OVERVIEW      

11.1.2   PRODUCT OVERVIEW 

11.1.3   FINANCIALS    

11.1.4   KEY DEVELOPMENTS

11.2      ABIOGEN PHARMA

11.2.1   OVERVIEW      

11.2.2   PRODUCT OVERVIEW 

11.2.3   FINANCIALS    

11.2.4   KEY DEVELOPMENTS

11.3      ACTELION PHARMACEUTICALS

11.3.1   OVERVIEW

11.3.2   PRODUCT OVERVIEW 

11.3.3   FINANCIALS

11.3.4   STRATEGY      

11.3.5   KEY DEVELOPMENT   

11.4      ALLOS THERAPEUTICS

11.4.1   OVERVIEW

11.4.2   PRODUCT OVERVIEW

11.4.3   FINANCIALS

11.4.4   KEY DEVELOPMENTS

11.5      BRISTOL-MYERS SQUIBB COMPANY

11.5.1   OVERVIEW

11.5.2   PRODUCT OVERVIEW 

11.5.3   FINANCIALS    

11.5.4   KEY DEVELOPMENTS

11.6      OTHERS